295 related articles for article (PubMed ID: 3275684)
1. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients.
Mattei AM; Ferrari C; Baroldi P; Cavioni V; Paracchi A; Galparoli C; Romano C; Spellecchia D; Gerevini G; Crosignani PG
J Clin Endocrinol Metab; 1988 Jan; 66(1):193-8. PubMed ID: 3275684
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline: long-acting oral treatment of hyperprolactinemic disorders.
Ferrari C; Mattei A; Melis GB; Paracchi A; Muratori M; Faglia G; Sghedoni D; Crosignani PG
J Clin Endocrinol Metab; 1989 Jun; 68(6):1201-6. PubMed ID: 2656736
[TBL] [Abstract][Full Text] [Related]
3. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group.
Webster J; Piscitelli G; Polli A; Ferrari CI; Ismail I; Scanlon MF
N Engl J Med; 1994 Oct; 331(14):904-9. PubMed ID: 7915824
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G
J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients.
Ferrari C; Barbieri C; Caldara R; Mucci M; Codecasa F; Paracchi A; Romano C; Boghen M; Dubini A
J Clin Endocrinol Metab; 1986 Oct; 63(4):941-5. PubMed ID: 3745407
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
8. [Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study].
Pascal-Vigneron V; Weryha G; Bosc M; Leclere J
Presse Med; 1995 Apr; 24(16):753-7. PubMed ID: 7784413
[TBL] [Abstract][Full Text] [Related]
9. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of hyperprolactinemic amenorrhea with cabergoline].
Fideleff HL; Holland ME; Chervin A; Gurucharri C; Sinai I
Medicina (B Aires); 1997; 57(6):657-61. PubMed ID: 9674185
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline in the long-term therapy of hyperprolactinemic disorders.
Ferrari C; Paracchi A; Mattei AM; de Vincentiis S; D'Alberton A; Crosignani P
Acta Endocrinol (Copenh); 1992 Jun; 126(6):489-94. PubMed ID: 1642081
[TBL] [Abstract][Full Text] [Related]
12. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients.
Ferrari C; Paracchi A; Romano C; Gerevini G; Boghen M; Barreca A; Fortini P; Dubini A
Clin Endocrinol (Oxf); 1988 Nov; 29(5):467-76. PubMed ID: 2908102
[TBL] [Abstract][Full Text] [Related]
14. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
[TBL] [Abstract][Full Text] [Related]
15. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline.
Moro M; Inada Y; Kojima M; Miyata H; Komatsu H; Torii R
Eur J Pharmacol; 1999 Feb; 368(1):57-66. PubMed ID: 10096770
[TBL] [Abstract][Full Text] [Related]
16. Dose-related prolactin inhibitory effect of the new long-acting dopamine receptor agonist cabergoline in normal cycling, puerperal, and hyperprolactinemic women.
Melis GB; Gambacciani M; Paoletti AM; Beneventi F; Mais V; Baroldi P; Fioretti P
J Clin Endocrinol Metab; 1987 Sep; 65(3):541-5. PubMed ID: 3624413
[TBL] [Abstract][Full Text] [Related]
17. Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.
Lissoni P; Vaghi M; Pescia S; Rovelli F; Ardizzola A; Valtulina F; Malugani F; Gardani G; Tancini G
J Biol Regul Homeost Agents; 2004; 18(3-4):291-4. PubMed ID: 15786695
[TBL] [Abstract][Full Text] [Related]
18. Recurrence of hyperprolactinemia and continuation of ovarian acyclicity in captive African elephants (Loxodonta africana) treated with cabergoline.
Morfeld KA; Ball RL; Brown JL
J Zoo Wildl Med; 2014 Sep; 45(3):569-76. PubMed ID: 25314824
[TBL] [Abstract][Full Text] [Related]
19. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer.
Frontini L; Lissoni P; Vaghi M; Perego MS; Pescia S; Ardizzoia A; Gardani G
Anticancer Res; 2004; 24(6):4223-6. PubMed ID: 15736476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
